Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors

Fig. 1

Fold-changes relative to baseline. Fold-changes are shown by lymphocyte populations in peripheral blood following treatment with utomilumab and mogamulizumab. Results were aggregated across all utomilumab doses, as statistically significant differences between utomilumab doses were not observed. a Major T-cell subpopulations relative to all white blood cells; b Treg and other major CD4+ T- cell populations; and (c) major CD8+ T-cell populations. White blood cells were defined by forward and side light scatter. T cells were defined by co-expression of CD3, CD4, and CD8. Naïve, central memory, and effector memory T-cell subpopulations were defined as CD45RA+CCR7+, CD45RACCR7+, and CD45RACCR7, respectively [32]. Tregs were defined as CD3+CD4+CD25+CD127low/ −[33]. Treg, regulatory T cell

Back to article page